Observational studyTuberculosis (Edinburgh, Scotland)2020
Cross-validation of existing signatures and derivation of a novel 29-gene transcriptomic signature predictive of progression to TB in a Brazilian cohort of household contacts of pulmonary TB.
Observational study in Tuberculosis (Edinburgh, Scotland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Biomarker tests of progression from tuberculosis infection to disease: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Gene signature discovery and systematic validation across diverse clinical cohorts for TB prognosis and response to treatment.PLoS computational biology · 2023Pooled it
- Increasing reproducibility, robustness, and generalizability of biomarker selection from meta-analysis using Bayesian methodology.PLoS computational biology · 2022Pooled it
- Monocyte-Amplified Transcriptional Signatures of Human Diseases.bioRxiv : the preprint server for biology · 2026Article
- Immunometabolic reprogramming ofFrontiers in tuberculosis · 2026Article
- Peripheral blood cellular dynamics during the progression of human tuberculosis.Scientific reports · 2025Article
- Prominence of Mycobacterium tuberculosis biomarkers among sputum culture-negative clinic attendees, independent of Ultra status.Journal of infection and public health · 2025Article
- Analysis of the cross-study replicability of tuberculosis gene signatures using 49 curated human transcriptomic datasets.Tuberculosis (Edinburgh, Scotland) · 2025Article
- Multiplexed cytokine profiling identifies diagnostic signatures for latent tuberculosis and reactivation risk stratification.PloS one · 2025Article
- Evaluation of host-immune biomarker signatures as multiplex qPCR diagnostic assays: a pilot study toward meeting WHO target product profiles for TB diagnosis in India.Frontiers in tuberculosis · 2025Article
- Comparison of gene set scoring methods for reproducible evaluation of tuberculosis gene signatures.BMC infectious diseases · 2024Article
- Multi-cohort analysis reveals immune subtypes and predictive biomarkers in tuberculosis.Scientific reports · 2024Article
- Article
- NCoR1 controls Mycobacterium tuberculosis growth in myeloid cells by regulating the AMPK-mTOR-TFEB axis.PLoS biology · 2023Article
- Research progress on genetic control of host susceptibility to tuberculosis.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022Review
- Development and Validation of a Parsimonious Tuberculosis Gene Signature Using the digital NanoString nCounter Platform.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Malnutrition leads to increased inflammation and expression of tuberculosis risk signatures in recently exposed household contacts of pulmonary tuberculosis.Frontiers in immunology · 2022Article
- Tuberculosis-Learning the Impact of Nutrition (TB LION): protocol for an interventional study to decrease TB risk in household contacts.BMC infectious diseases · 2021Article
- Reduced thyroxine production in young household contacts of tuberculosis patients increases active tuberculosis disease risk.JCI insight · 2021Article
- Symptom Screens Are Not Sufficient: The Fight Against Tuberculosis Needs Better Weapons.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The goal of this study was to identify individuals at risk of progression and reactivation among household contacts (HHC) of pulmonary TB cases in Vitoria, Brazil. We first evaluated the predictive performance of six published signatures on the transcriptional dataset obtained from peripheral blood mononuclear cell samples from HHC that either progressed to TB disease or not (non-progressors) during a five-year follow-up. The area under the curve (AUC) values for the six signatures ranged from 0.670 to 0.461, and the PPVs did not reach the WHO published target product profiles (TPPs). We therefore used as training cohort the earliest time-point samples from the African cohort of adolescents (GSE79362) and applied an ensemble feature selection pipeline to derive a novel 29-gene signature (PREDICT29). PREDICT29 was tested on 16 progressors and 21 non-progressors. PREDICT29 performed better in segregating progressors from non-progressors in the Brazil cohort with the area under the curve (AUC) value of 0.911 and PPV of 20%. This proof of concept study demonstrates that PREDICT29 can predict risk of progression/reactivation to clinical TB disease in recently exposed individuals at least 5 years prior to disease development. Upon validation in larger and geographically diverse cohorts, PREDICT29 can be used to risk-stratify recently infected for targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.